# What Is Trulicity? How Dulaglutide Works and What It Is Approved For

By Ruth Calder, Enforcement Editor (https://glpwatchdog.org/authors/ruth-calder) | Published: 2026-11-16

Canonical page: https://glpwatchdog.org/research/what-is-trulicity

> Trulicity (dulaglutide) is a once-weekly GLP-1 receptor agonist from Eli Lilly, FDA-approved since 2014 for type 2 diabetes and to lower heart risk. How it works, its doses, its side effects, what REWIND found and how it compares with Ozempic and Mounjaro.

## Key points

- Trulicity is dulaglutide, a once-weekly GLP-1 receptor agonist from Eli Lilly, first approved in 2014.
- Its label covers blood sugar control in type 2 diabetes from age 10 upward, and lowering heart risk in adults with type 2 diabetes.
- Adult doses start at 0.75 mg and can rise in steps to 4.5 mg once a week.
- In REWIND, major cardiovascular events were 12.0% on dulaglutide and 13.4% on placebo.
- At 1.5 mg, the label's placebo-controlled trials show nausea in 21.1%, diarrhea in 12.6% and vomiting in 12.7%.

Trulicity is a once-weekly injection of dulaglutide, [a GLP-1 receptor agonist](https://glpwatchdog.org/research/which-drugs-are-glp1s) made by Eli Lilly and first approved by the FDA in 2014. The label gives it two jobs, both in type 2 diabetes: bringing down blood sugar, from age 10 upward, and in adults with heart disease or several risk factors, making heart attack, stroke and death from heart disease less likely.[1] It is not insulin, it is not semaglutide, and it has no weight-loss approval.

> **About this article.** Written from the current FDA label on DailyMed and the main published trials of dulaglutide. Trial results describe groups, and a decision about your own treatment belongs with your prescriber.

## What is Trulicity used for?

*Trulicity's FDA-approved uses*

| Use | Who | Evidence behind it |
| --- | --- | --- |
| Blood sugar control, with diet and exercise | Type 2 diabetes, age 10 and up | Glycemic trials in adults and one pediatric trial |
| Fewer major heart and stroke events | Adults with type 2 diabetes plus heart disease or multiple risk factors | REWIND |

Both uses require type 2 diabetes.[1] Anything else, weight loss included, is off-label, a point worked through with the numbers in [Trulicity for weight loss](https://glpwatchdog.org/research/trulicity-for-weight-loss). The drug’s fuller record, with sellers and prices, is on our [Trulicity drug page](https://glpwatchdog.org/drugs/trulicity).

## Is Trulicity a GLP-1, and how does it work?

Yes. Dulaglutide activates the receptor for GLP-1, a hormone the gut releases after eating. In the pancreas this prompts insulin release that depends on glucose, so the signal is strongest when blood sugar is high. It also lowers glucagon, the hormone that tells the liver to release sugar, and it slows the stomach, most of all after the first dose, with the effect fading as doses continue.[1]

Its build is what sets it apart. Dulaglutide is a fusion protein: two identical chains, each with a GLP-1-like segment attached to part of a human antibody. The GLP-1 segment is 90% similar to the natural hormone, altered at the spot where the enzyme DPP-4 normally attacks it. The half-life is about 5 days, which is what makes weekly dosing work.[1]

People often assume that a drug prompting insulin release must be insulin. It is not, and the difference between Trulicity and insulin matters if you take both.

## How well does Trulicity lower blood sugar?

In the trial behind the higher doses, 1,842 adults on metformin with an average HbA1c of 8.6% took 1.5, 3 or 4.5 mg weekly. At 36 weeks the label shows HbA1c down 1.5, 1.6 and 1.8 points.[1][3] Results in routine care look smaller. In a 2026 study of 403 patients at one hospital who stayed on dulaglutide for at least 3 years, HbA1c fell 1.1 points over a mean of 4.3 years, in a retrospective study with no comparison group.[7]

## Does Trulicity protect the heart?

REWIND is the reason for the heart indication. It assigned 9,901 people with type 2 diabetes by chance to weekly dulaglutide 1.5 mg or a placebo, then followed them for a median of 5.4 years. The combined tally of heart attacks, strokes and cardiovascular deaths reached 12.0% against 13.4%, a hazard ratio of 0.88. Deaths from any cause did not differ significantly (hazard ratio 0.90, 95% CI 0.80 to 1.01).[2] Many participants had risk factors and no prior event, which is why the label covers both groups.[1]

That record made dulaglutide the comparator for tirzepatide in SURPASS-CVOT, where tirzepatide proved no worse (12.2% against 13.1%, hazard ratio 0.92) but did not reach superiority.[5] Its kidney results are in [tirzepatide versus dulaglutide on the kidneys](https://glpwatchdog.org/research/tirzepatide-vs-dulaglutide-kidney). Against empagliflozin, an observational 2025 study in Annals of Internal Medicine found similar risks for dulaglutide (hazard ratio 1.03). Semaglutide’s figure in the same study was 0.89, which did not reach significance, and the design leaves room for confounding.[6]

## What are the Trulicity doses?

*Trulicity dosing on the FDA label*

| Step | Adults | Children 10 and older |
| --- | --- | --- |
| Start | 0.75 mg once a week | 0.75 mg once a week |
| After at least 4 weeks | May rise to 1.5 mg | May rise to 1.5 mg, the maximum |
| If more control is needed | Rise by 1.5 mg after at least 4 weeks on each dose | Not applicable |
| Maximum | 4.5 mg once a week | 1.5 mg once a week |

Each strength comes as a single-dose pen injected under the skin, once a week, at any time of day and with or without food. If you miss a dose, the label says to take it if at least 3 days remain until the next scheduled one.[1] The label recommends no dose adjustment for kidney impairment, though it asks for kidney monitoring in anyone with impaired function who develops severe stomach side effects.[1]

## What are the side effects of Trulicity?

The common ones are in the gut, and they rise with dose. The figures below are from the label’s pooled placebo-controlled trials.[1] In REWIND, over more than five years, 47.4% of people on dulaglutide reported a stomach side effect against 34.1% on placebo.[2]

*Side effects in the label's placebo-controlled trials*

| Side effect | Placebo | 0.75 mg | 1.5 mg |
| --- | --- | --- | --- |
| Nausea | 5.3% | 12.4% | 21.1% |
| Diarrhea | 6.7% | 8.9% | 12.6% |
| Vomiting | 2.3% | 6.0% | 12.7% |
| Decreased appetite | 1.6% | 4.9% | 8.6% |

The label’s boxed warning concerns thyroid C-cell tumors seen in rodents, whose relevance to people has not been determined. People must not take Trulicity if they or a relative have had medullary thyroid carcinoma, if they have MEN 2, or if it has caused them a serious allergic reaction. The other warnings are pancreatitis, lows when paired with insulin or a sulfonylurea, allergic reactions, dehydration-related kidney injury, severe stomach problems, worsening diabetic eye disease, gallbladder disease and aspiration under anesthesia. Because it slows the stomach, it can also reduce how fast oral medicines are absorbed.[1]

## How does Trulicity compare with Ozempic and Mounjaro?

Semaglutide has beaten it directly. In SUSTAIN 7, an open-label trial funded by semaglutide’s maker, Ozempic 1 mg lowered HbA1c by 1.8 points and weight by 6.5 kg over 40 weeks, against 1.4 points and 3.0 kg for Trulicity 1.5 mg. Trulicity’s higher doses were not part of that test.[4] The side-by-side details are in [Ozempic vs Trulicity](https://glpwatchdog.org/compare/drugs/ozempic-vs-trulicity) and [Trulicity vs Mounjaro](https://glpwatchdog.org/compare/drugs/trulicity-vs-mounjaro). What it costs to fill is covered in Trulicity cost.

## Frequently asked questions

### What is Trulicity used for?

Type 2 diabetes is the only condition on its label. It is approved to bring down blood sugar from age 10 upward, and to make heart attack, stroke and death from heart disease less likely in adults with diabetes who also have heart disease or several risk factors.

### Is Trulicity a GLP-1?

Yes. Dulaglutide, the active ingredient, belongs to the GLP-1 receptor agonist class. It is a fusion protein with a half-life of about 5 days, which is why it is injected once a week.

### Is Trulicity the same as Ozempic?

No. Trulicity is dulaglutide, made by Eli Lilly. Ozempic is semaglutide, made by Novo Nordisk. Both are weekly GLP-1 injections for type 2 diabetes, but in the head-to-head SUSTAIN 7 trial Ozempic 1 mg lowered blood sugar and weight more than Trulicity 1.5 mg.

### How does Trulicity make you feel?

Stomach effects are the most common complaint. In the label's placebo-controlled trials at 1.5 mg, 21.1% had nausea, 12.6% diarrhea and 12.7% vomiting. The label also reports fatigue in 5.6%.

### Who should not take Trulicity?

The label rules it out if you or a relative have had medullary thyroid carcinoma, if you have MEN 2, or if dulaglutide or an ingredient of the pen has caused you a serious allergic reaction.

## References

1. Eli Lilly and Company TRULICITY (dulaglutide) injection, for subcutaneous use: prescribing information. DailyMed, U.S. National Library of Medicine. 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=463050bd-2b1c-40f5-b3c3-0a04bb433309
2. Gerstein HC, Colhoun HM, Dagenais GR, et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet. 2019. PMID: 31189511. DOI: 10.1016/S0140-6736(19)31149-3. https://pubmed.ncbi.nlm.nih.gov/31189511/
3. Frias JP, Bonora E, Nevarez Ruiz L, et al. Efficacy and Safety of Dulaglutide 3.0 mg and 4.5 mg Versus Dulaglutide 1.5 mg in Metformin-Treated Patients With Type 2 Diabetes in a Randomized Controlled Trial (AWARD-11). Diabetes Care. 2021. PMID: 33397768. DOI: 10.2337/dc20-1473. https://pubmed.ncbi.nlm.nih.gov/33397768/
4. Pratley RE, Aroda VR, Lingvay I, et al. Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial. Lancet Diabetes Endocrinol. 2018. PMID: 29397376. DOI: 10.1016/S2213-8587(18)30024-X. https://pubmed.ncbi.nlm.nih.gov/29397376/
5. Nicholls SJ, Pavo I, Bhatt DL, et al. Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes. N Engl J Med. 2025. PMID: 41406444. DOI: 10.1056/NEJMoa2505928. https://pubmed.ncbi.nlm.nih.gov/41406444/
6. Saeed A, Mulukutla SR, Thoma F, et al. Comparison of Semaglutide or Dulaglutide Versus Empagliflozin for Risk for Death and Cardiovascular Outcomes Among Patients With Type 2 Diabetes: Two Target Trial Emulation Studies. Ann Intern Med. 2025. PMID: 40523289. DOI: 10.7326/ANNALS-24-00775. https://pubmed.ncbi.nlm.nih.gov/40523289/
7. Kim HS, Kim MJ, Kim HS, et al. Real-World Evidence of Long-Term Dulaglutide Use: Sustained Glycemic and Weight Improvements Beyond Three Years. Clin Endocrinol (Oxf). 2026. PMID: 41387176. DOI: 10.1111/cen.70078. https://pubmed.ncbi.nlm.nih.gov/41387176/

---

Cite as: GLP Watchdog, Ruth Calder, "What Is Trulicity? How Dulaglutide Works and What It Is Approved For", published 2026-11-16. https://glpwatchdog.org/research/what-is-trulicity

Canonical HTML page: https://glpwatchdog.org/research/what-is-trulicity

Medical disclaimer: Nothing here is medical advice. We report on this subject; we do not treat anyone. Whether to begin a medication, supplement, or treatment, whether to adjust it, and whether to stop are questions for a clinician licensed to answer them, who knows your history.
